

State of Oklahoma  
Oklahoma Health Care Authority  
**Kisqali® Femara® Co-Pack (Ribociclib/Letrozole) and Kisqali®  
(Ribociclib) Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_

**Drug Information**

**Drug Name:** \_\_\_\_\_ **Strength:** \_\_\_\_\_ **Pharmacy billing (NDC:** \_\_\_\_\_ **)**  
**Daily Dose:** \_\_\_\_\_ **Refill Number:** \_\_\_\_\_ **Start Date (or date of next dose):** \_\_\_\_\_

**Billing Provider Information**

**Provider NPI:** \_\_\_\_\_ **Provider Name:** \_\_\_\_\_  
**Provider Phone:** \_\_\_\_\_ **Provider Fax:** \_\_\_\_\_

**Prescriber Information**

**Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_  
**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_

**Criteria**

**For Initial Authorization:**

1. Diagnosis of advanced or metastatic breast cancer? Yes \_\_\_ No \_\_\_
2. If answer is 'no' from previous question, please indicate diagnosis: \_\_\_\_\_
3. Is this being used for first line use? Yes \_\_\_ No \_\_\_
4. Please indicate requested information:
  - Negative expression of Human Epidermal Receptor Type 2 (HER2)
  - Patient is postmenopausal
  - Estrogen receptor (ER)-positive
5. Will Kisqali® be used in combination with an aromatase inhibitor? Yes \_\_\_ No \_\_\_
6. Will Kisqali® be used in combination with fulvestrant? Yes \_\_\_ No \_\_\_
  - b. If answer is 'yes' from previous question, is this being used as initial endocrine based therapy or following disease progression on endocrine therapy? Yes \_\_\_ No \_\_\_

Additional Information: \_\_\_\_\_

**For Continued Authorization:**

1. Date of last dose: \_\_\_\_\_
2. Does patient have any evidence of progressive disease while on ribociclib? Yes \_\_\_ No \_\_\_
3. Has the member experienced any adverse drug reactions related to ribociclib therapy? Yes \_\_\_ No \_\_\_

*If yes, please specify adverse reactions:* \_\_\_\_\_

Additional Information: \_\_\_\_\_

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

***I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.***

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*